RT Journal Article
SR Electronic
T1 Trends of MBT drug resistance
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2864
VO 42
IS Suppl 57
A1 Liudmila Pankratova
A1 Inna Volchkova
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P2864.abstract
AB We conducted 2182 MBT sensitivity tests in the tuberculosis hospital, Saratov (Russia), for assessment of mycobacterium tuberculosis (MBT) drug resistance (DR).From 2006 to 2012, MBT DR increased from 67.6% to 87.1%, primary MBT DR doubled - from 36.6% to 71.4%, secondary DR increased from 82.1 to 89.7%. By 2012, multiple drug resistance (MDR) reached 67.2%, including the increase of primary MDR from 16.8% to 40.0, and of secondary MDR from 53.8% to 71.1%.There is a first-line drug DR increase from 2008 to 2012:• DR to H has gone up from 44.1% to 76.8% (primary from 16.8% to 57.1%; secondary from 57.0% to 79.7%)• DR to R increased from 44.4% to 70.9% (primary from 16.8% to 40.0%; secondary from 57.3% to 75.4%)• DR to E increased from 24.2% to 57.9% (primary from 5.6% to 37.1%; secondary from 32.5% to 61.6%)• DR to S increased from 69.2% to 80.1% (primary reached 65.7%, secondary 82.3%, DR among the chronically ill was 93.4%)In 2012, second-line drug DR was 67.5%, primary DR - 40.0%, secondary DR - 72.4%. From 2008 to 2012• DR to PAS increased from 15.2% to 37.3% (primary 8.6%, secondary 42.2%)• DR to Ofl increased from 18.7% to 29.2% (among new patients - 14.3%, secondary is 31.9%)• DR to Capr remained stable - 23.3% (primary increased from 5.9% to 20.0%, secondary did not change - 24.1%)• DR to K has doubled from 26.3% to 50.2% (primary 22.9%, secondary 54.7%)CONCLUSIONSThe DR reduction trend that emerged in 2011 has been replaced with further DR growth, mainly to the first-line drugs where it has reached alarming proportions. It is vitally important to introduce rapid sensitivity testing methods, as standard chemotherapy regimens (I, II, III) require the use of first-line drugs.